A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 28, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Apr 2, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PHVS SEC filings page.
This page shows Pharvaris N.V. (PHVS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Pharvaris N.V. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Pharvaris N.V. passes 1 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Pharvaris N.V. reported a net loss of $206.2M while operations used $160.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Pharvaris N.V. reported an operating loss of $203.9M against $503K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Pharvaris N.V. reported a net loss of $206.2M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Pharvaris N.V. earned -$3.49 per diluted share (EPS) in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Pharvaris N.V. recorded an outflow of $161.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
Pharvaris N.V. held $342.3M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Margins & Returns
Pharvaris N.V.'s ROE was -64.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 14.6 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Pharvaris N.V. invested $146.1M in research and development in fiscal year 2025. This represents an increase of 43.2% from the prior year.
Pharvaris N.V. invested $193K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 65.3% from the prior year.
Not reported for fiscal year 2025.
PHVS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $146.1M+43.2% | $102.0M+40.6% | $72.5M+18.2% | $61.4M+51.5% | $40.5M+69.8% | $23.9M+273.8% | $6.4M+52.8% | $4.2M |
| Operating Income | -$203.9Mn/m | -$137.0Mn/m | -$110.4Mn/m | -$80.9Mn/m | -$48.3Mn/m | -$31.9Mn/m | -$9.0Mn/m | -$4.9M |
| Interest Expense | $503K-2.8% | $518K+2861.5% | $17K+1.5% | $17K-94.3% | $303K+167.7% | $113K+496.7% | $19K+4253.6% | $435 |
| Income Tax | $2.3M+23.5% | $1.9M+62.8% | $1.2M+59.7% | $726K+815.5% | $79Kn/m | -$102Kn/m | $0n/m | $0 |
| Net Income | -$206.2Mn/m | -$138.9Mn/m | -$111.6Mn/m | -$81.7Mn/m | -$48.3Mn/m | -$31.8Mn/m | -$9.0Mn/m | -$4.9M |
| EPS (Basic) | -$3.49n/m | -$2.57n/m | -$2.91n/m | -$2.43n/m | -$1.58 | N/A | N/A | N/A |
| EPS (Diluted) | -$3.49n/m | -$2.57n/m | -$2.91n/m | -$2.43n/m | -$1.58 | N/A | N/A | N/A |
| Diluted Shares (Avg) | 59M+9.5% | 54M+40.7% | 38M+14.3% | 34M+10.4% | 30M | 5M0.0% | 5M0.0% | 5M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, SG&A Expenses, EBITDA.
PHVS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $353.8M+17.3% | $301.6M-31.6% | $441.0M+145.8% | $179.4M-25.2% | $240.0M+94.1% | $123.6M+434.7% | $23.1M | N/A |
| Cash & Equivalents | $342.3M+17.8% | $290.6M-32.9% | $432.8M+150.0% | $173.1M-26.9% | $236.9M+96.4% | $120.6M+428.6% | $22.8M+269.9% | $6.2M |
| Accounts Receivable | $5.3M+75.2% | $3.0M+165.2% | $1.1M+180.9% | $409K-48.4% | $792K+13.7% | $697K+194.3% | $237K | N/A |
| Total Liabilities | $35.4M+44.9% | $24.4M+50.9% | $16.2M-18.0% | $19.8M+144.7% | $8.1M+24.3% | $6.5M+200.8% | $2.2M | N/A |
| Total Equity | $318.4M+14.9% | $277.2M-34.8% | $424.8M+166.1% | $159.7M-31.2% | $232.0M+98.0% | $117.1M+458.8% | $21.0M+269.5% | $5.7M |
| Retained Earnings | -$680.2Mn/m | -$416.4Mn/m | -$294.2Mn/m | -$175.6Mn/m | -$99.1Mn/m | -$54.4Mn/m | -$20.7M | N/A |
Not reported in any period shown, so not listed: Current Assets, Short-Term Investments, Inventory, Long-Term Investments, Goodwill, Current Liabilities, Non-Current Liabilities, Long-Term Debt.
PHVS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$160.9Mn/m | -$124.3Mn/m | -$102.9Mn/m | -$71.9Mn/m | -$50.5Mn/m | -$26.3Mn/m | -$7.5Mn/m | -$4.5M |
| Capital Expenditures | $193K-65.3% | $557K+459.5% | $100K-25.1% | $133K-9.6% | $147K+180.0% | $53K+247.4% | $15Kn/m | $0 |
| Free Cash Flow | -$161.1Mn/m | -$124.9Mn/m | -$103.0Mn/m | -$72.0Mn/m | -$50.6Mn/m | -$26.3Mn/m | -$7.5Mn/m | -$4.5M |
| Investing Cash Flow | -$193Kn/m | -$557Kn/m | -$100Kn/m | -$133Kn/m | -$147Kn/m | -$53Kn/m | -$15Kn/m | $0 |
| Financing Cash Flow | $188.5M+6703.4% | $2.8M-99.2% | $359.9M+3789.6% | $9.3M-94.3% | $162.6M+31.4% | $123.8M+409.6% | $24.3M+370.2% | $5.2M |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Dividends Paid, Share Buybacks.
PHVS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -64.8%-14.6pp | -50.1%-23.9pp | -26.3%+24.9pp | -51.1%-30.3pp | -20.8%+6.3pp | -27.1%+15.9pp | -43.0%+44.1pp | -87.1% |
| Return on Assets | -58.3%-12.2pp | -46.1%-20.8pp | -25.3%+20.2pp | -45.5%-25.4pp | -20.1%+5.6pp | -25.7%+13.3pp | -39.0% | N/A |
| Liabilities-to-Equity | 0.110.0x | 0.09+0.1x | 0.04-0.1x | 0.12+0.1x | 0.030.0x | 0.060.0x | 0.10 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Current Ratio, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Pharvaris N.V. PHVS | FY2025 | N/A | -$206.2M | N/A | $2.3B | — |
| Ardelyx, Inc. ARDX | FY2025 | $407.3M | -$61.6M | -15.1% | $800.4M | 45/100 |
| Edgewise Therapeutics, Inc. EWTX | FY2025 | N/A | -$167.8M | N/A | $4.4B | — |
| Biohaven Ltd. BHVN | FY2025 | N/A | -$738.8M | N/A | $2.3B | — |
| Mannkind Corporation MNKD | FY2025 | $349.0M | $5.9M | 1.7% | $1.1B | 50/100 |
Where Pharvaris N.V. Ranks
Frequently Asked Questions
Is Pharvaris N.V. profitable?
No, Pharvaris N.V. (PHVS) reported a net loss of $206.2M in fiscal year 2025.
What is Pharvaris N.V.'s return on equity (ROE)?
Pharvaris N.V. (PHVS) has a return on equity of -64.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Pharvaris N.V.'s free cash flow?
Pharvaris N.V. (PHVS) recorded an outflow of $161.1M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Pharvaris N.V.'s operating cash flow?
Pharvaris N.V. (PHVS) recorded an outflow of $160.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Pharvaris N.V.'s total assets?
Pharvaris N.V. (PHVS) had $353.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Pharvaris N.V.'s capital expenditures?
Pharvaris N.V. (PHVS) invested $193K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Pharvaris N.V. spend on research and development?
Pharvaris N.V. (PHVS) invested $146.1M in research and development during fiscal year 2025.
What is Pharvaris N.V.'s liabilities-to-equity ratio?
Pharvaris N.V. (PHVS) had a liabilities-to-equity ratio of 0.11 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is Pharvaris N.V.'s return on assets (ROA)?
Pharvaris N.V. (PHVS) had a return on assets of -58.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Pharvaris N.V.'s P/E ratio?
Pharvaris N.V. (PHVS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $2.3B as of Oct 28, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Pharvaris N.V.'s price-to-sales ratio?
Pharvaris N.V. (PHVS) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $2.3B as of Oct 28, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Pharvaris N.V.'s Piotroski F-Score?
Pharvaris N.V. (PHVS) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Pharvaris N.V.'s earnings high quality?
Pharvaris N.V. (PHVS) reported a net loss of $206.2M while operations used $160.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Pharvaris N.V. cover its interest payments?
Pharvaris N.V. (PHVS) reported an operating loss of $203.9M against $503K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.